Inhaled sphingosine has no adverse side effects in isolated ventilated and perfused pig lungs

• Published in: Scientific reports Vol. 11; no. 1; p. 18607
• Main Authors: Carstens, Henning, Kalka, Katharina, Verhaegh, Rabea, Schumacher, Fabian, Soddemann, Matthias, Wilker, Barbara, Keitsch, Simone, Sehl, Carolin, Kleuser, Burkhard, Wahlers, Thorsten, Reiner, Gerald, Koch, Achim, Rauen, Ursula, Gulbins, Erich, Kamler, Markus
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20.09.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154/1438; 631/154/152; 692/699/255; Antibiotics; Bronchopulmonary infection; Bronchus; Ceramide; Corticoids; Corticosteroids; E coli; Epithelial cells; Humanities and Social Sciences; Inhalation; Lung transplantation; Lungs; multidisciplinary; Paraffin; Perfusion; Respiratory tract; Science; Science (multidisciplinary); Side effects; Trachea; Ventilation
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-97708-3

Ex-vivo lung perfusion (EVLP) systems like XVIVO are more and more common in the setting of lung transplantation, since marginal donor-lungs can easily be subjected to a performance test or be treated with corticosteroids or antibiotics in high dose regimes. Donor lungs are frequently positive in bronchoalveolar lavage (BAL) bacterial cultures (46–89%) which leads to a donor-to-recipient transmission and after a higher risk of lung infection with reduced posttransplant outcome. We have previously shown that sphingosine very efficiently kills a variety of pathogens, including Pseudomonas aeruginosa , Staphylococcus aureus and epidermidis , Escherichia coli or Haemophilus influenzae . Thus, sphingosine could be a new treatment option with broadspectrum antiinfective potential, which may improve outcome after lung transplantation when administered prior to lung re-implantation. Here, we tested whether sphingosine has any adverse effects in the respiratory tract when applied into isolated ventilated and perfused lungs. A 4-h EVLP run using minipig lungs was performed. Functional parameters as well as perfusate measurements where obtained. Biopsies were obtained 30 min and 150 min after inhalation of sphingosine. Tissue samples were fixed in paraformaldehyde, embedded in paraffin and sectioned. Hemalaun, TUNEL as well as stainings with Cy3-coupled anti-sphingosine or anti-ceramide antibodies were implemented. We demonstrate that tube-inhalation of sphingosine into ex-vivo perfused and ventilated minipig lungs results in increased levels of sphingosine in the luminal membrane of bronchi and the trachea without morphological side effects up to very high doses of sphingosine. Sphingosine also did not affect functional lung performance. In summary, the inhalation of sphingosine results in an increase of sphingosine concentrations in the luminal plasma membrane of tracheal and bronchial epithelial cells. The inhalation has no local side effects in ex-vivo perfused and ventilated minipig lungs.